Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (22)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Armand, J. P.
Right arrow Articles by Clavel, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Armand, J. P.
Right arrow Articles by Clavel, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 7:837-842, 1996
© 1996 European Society for Medical Oncology

research-article

Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies

J. P. Armand1,, Y. M. Extra2, G. Catimel3, D. Abigerges1, M. Marty2 and M. Clavel3

1Institut Gustave-Roussy Villejuif
2Hôpital St. Louis Paris
3Centre Léon Bérard Lyon, France

Correspondence to: Jean Pierre Armand, MD Institut Gustave-Roussy 39 rue Camille Desmoulins 94805 Villejuif Cedex France

BACKGROUND:: CPT-11 (irinotecan), a camptothecin-derived anticancer agent with DNA topoisomerase 1 inhibitory activity, has demonstrated a broad spectrum of in vitro and in vivo activity in solid tumour models including multidrug-resistant tumours. This review details the rationale for the dosage schedule of CPT-11 selected for phase II studies, based on the results of 3 European phase I dose-escalating trials in patients with solid tumours.

PATIENTS AND METHODS:: CPT-11 was administered as a 30-minute intravenous infusion once every 3 weeks (schedule 1), once daily for 3 consecutive days every 3 weeks (schedule 2) or once weekly every 3 out of 4 weeks (schedule 3).

RESULTS:: Neutropenia and diarrhoea were the major doselimiting toxicities in all of the studies. The maximum tolerated dose of CPT-11 was 115 and 145 mg/m2/day for schedules 2 and 3, respectively. With schedule 1, diarrhoea became dose-limiting at 350 mg/m2 but was manageable with highdose loperamide therapy.

CONCLUSIONS:: CPT-11 350 mg/m2 administered as an intravenous infusion once every 3 weeks was chosen for further evaluation in early phase II studies, since this dosage regimen allowed the highest dose intensity with the least toxicity and was convenient for outpatient use. The place of higher doses (with intensive antidiarrhoeal support) and other administration schedules (e.g., protracted infusion) warrant further investigation.

chemotherapy, CPT-11, dosage schedules, irinotecan, DNA topoisomerase I inhibitor, solid tumours


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
J. L. Hyatt, L. Tsurkan, M. Wierdl, C. C. Edwards, M. K. Danks, and P. M. Potter
Intracellular inhibition of carboxylesterases by benzil: modulation of CPT-11 cytotoxicity.
Mol. Cancer Ther., September 1, 2006; 5(9): 2281 - 2288.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. M. Borner, J. Bernhard, D. Dietrich, R. Popescu, M. Wernli, P. Saletti, D. Rauch, R. Herrmann, D. Koeberle, H. Honegger, et al.
A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity
Ann. Onc., February 1, 2005; 16(2): 282 - 288.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
T. T. Batchelor, M. R. Gilbert, J. G. Supko, K. A. Carson, L. B. Nabors, S. A. Grossman, G. J. Lesser, T. Mikkelsen, S. Phuphanich, and for the NABTT CNS Consortium
Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11
Neuro-oncol, January 1, 2004; 6(1): 21 - 27.
[Abstract] [PDF]

Home page
 Jpn J Clin OncolHome page
S. Yalcin, B. Oksuzoglu, G. Tekuzman, H. Engin, I. Celik, A. Turker, I. Barista, I. Gullu, N. Guler, K. Altundag, et al.
Biweekly Irinotecan Plus Bolus 5-Fluorouracil and Folinic Acid in Patients with Advanced Stage Colorectal Cancer
Jpn. J. Clin. Oncol., November 1, 2003; 33(11): 580 - 583.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Vassal, F. Doz, D. Frappaz, K. Imadalou, E. Sicard, A. Santos, J. O'Quigley, C. Germa, M.-L. Risse, D. Mignard, et al.
A Phase I Study of Irinotecan As a 3-Week Schedule in Children With Refractory or Recurrent Solid Tumors
J. Clin. Oncol., October 15, 2003; 21(20): 3844 - 3852.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. Raymond, M. Fabbro, V. Boige, O. Rixe, M. Frenay, G. Vassal, S. Faivre, E. Sicard, C. Germa, J. M. Rodier, et al.
Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma
Ann. Onc., April 1, 2003; 14(4): 603 - 614.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. J. Hesketh
Defining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice
Oncologist, June 1, 1999; 4(3): 191 - 196.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.